A phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) nano-immunoconjugate therapy for metastatic gynecological malignancies: MC1371 (NCT02020707) (1308)
Matthew S. Block(Mayo Clinic in Arizona), Svetomir N. Markovic(Mayo Clinic), Carrie Strand(Mayo Clinic), Joel M. Reid(Children's Hospital of Philadelphia), Eleftheria Kalogera(Palmetto General Hospital), Andrea Wahner Hendrickson(Mayo Clinic in Arizona), Darragh O'Donoghue(Mayo Clinic in Arizona), Gretchen Glaser(Mayo Clinic), Wendy K. Nevala(Mayo Clinic), Aminah Jatoi(Mayo Clinic in Arizona), Jill M. Schimke(Mayo Clinic), Amanika Kumar(Mayo Clinic), Megan E. Grudem(Mayo Clinic), Vera J. Suman(Mayo Clinic), Carolyn M. Klampe(Mayo Clinic), Saravut J. Weroha(Mayo Clinic), Carrie Langstraat(Mayo Clinic)
Cited by 1
Related Papers
Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005)
|Journal of Clinical Oncology|2008|270
Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study
|Journal of Clinical Oncology|2008|210
Neurologic autoimmunity and immune checkpoint inhibitors
|Neurology|2020|158